Cassava Sciences Has More Data from Phase 2b Study of Sumifilam in Alzheimer’s

Alzheimer’s Patients Treated with Sumifilam Showed a Statistically Significant (p<0.001) Treatment Benefit on HMGB1,
a Protein that Triggers Neuroinflammation and Loss of Neurons

Alzheimer’s Patients Treated with Sumifilam Also Showed
a Treatment Benefit (p<0.05) on Blood-brain Barrier Integrity

Clinical Dataset to be Presented November 7^th at CTAD 2020 Conference

https://finance.yahoo.com/news/cassava-sciences-announces-additional-clinical-131500100.html